Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer's Phase 3 SigVie-002 study of sigvotatug vedotin in previously treated non-squamous NSCLC did not meet its primary endpoint of overall survival compared to docetaxel. Despite the overall miss, the company reported a stronger trend in overall survival and progression-free survival for the subset of patients who received only one prior line of therapy.
Key figures
- Drug Name
- sigvotatug vedotin
- Phase Of Trial
- Phase 3
- Participants enrolled
- 703
- Oncology breakthroughs goal by 2030
- 8
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.